The 146th Annual Meeting of the Pharmaceutical Society of Japan (Osaka)
Advanced Search

Session Details

Poster Presentation(C) Pharmaceutical Biology

[27-61-am]Bacteriology, Mycology, Parasitology, Virology 1

Fri. Mar 27, 2026 9:30 AM - 11:30 AM JST
Fri. Mar 27, 2026 12:30 AM - 2:30 AM UTC
Room 61 (4201, Bldg. 4, Area 4 [2F]) (3)
Discusser: Urata Shuzo, Yoshimi Tsuda

[27-61-am-21S]HSV-1-infected cells produce amyloid beta aggregates with neurotoxic activity.

○Kanemaki Sana1, Iwaisako Yuki1, Suga Kei2, Nakaso Kazuhiro3, Fujimuro Masahiro1 (1. Kyoto Pharmaceutical University, 2. Faculty of Medicine, Kyorin University, 3. Faculty of Medicine, Tottori University)

[27-61-am-22S]A pyridinium-type fullerene derivative reduced the viability of primary effusion lymphoma cells

○Nonoka Suzuki1, Jun Kawase1, Misa Takagi1, Ayano Kadota1, Misato Moriguchi 1, Tadashi Watanabe1, Shigeo Nakamura 2, Takumi Yasuno3, Tomoyuki Ohe3, Tadahiko Mashino3, Masahiro Fujimuro1 (1. Kyoto Pharm. Univ., 2. Nippon Medical School., 3. Keio Univ.)

[27-61-am-23S]Functional analysis of the glycosphingolipid sulfatide that promotes influenza A virus replication

○Naoto Haraguchi1, Yuuki Kurebayashi1, Yoshiki Wakabayashi1, Tadanobu Takahashi1, Yohei Tsukamoto1, Akira Minami1,2, Takashi Suzuki1, Hideyuki Takeuchi1 (1. Sch Pharm Sci., Univ of Shizuoka, 2. Fac Pharm., Juntendo Univ)

[27-61-am-24S]Analysis of the impact of O-glucose glycosylation on norovirus infection

○Naoki Oda1, Yuuki Kurebayashi1, Anju Nishiie1, Yohei Tsukamoto1, Akira Minami1,2, Tadanobu Takahashi1, Hideyuki Takeuchi1 (1. Sch.Pharm.Sci., Univ of Shizuoka, 2. Fac. Pharm., Juntendo Univ)

[27-61-am-25S]Molecular basis of anti-S2 antibody CvMab-62 binding to SARS-CoV-2 spike protein

○Fuwari Shishikura1, Gaiyi Wei2, Mizuki Moriya2, Kaoru Sato1, Mitsugu Yamada3, Momi Iwata3, Ryuichi Kato4, Miki Senda4, Masato Kawasaki4, Toshiya Senda4, Takeshi Murata5, Yuichiro Yamamoto2, Masayoshi Fukasawa2,6, Mika Kaneko7, Yukinari Kato7, Kohji Noguchi2,6 (1. Grad. Sch. Pharm. Sci., Tokyo Univ. Science, 2. Facult. Pharm. Sci., Tokyo Univ. Science, 3. Japan Aerospace Exploration Agency, JAXA, 4. High Energy Accelerator Research Organization, KEK, 5. Grad. Sch. Sci., Chiba Univ. , 6. JIHS, Dept. Biochem. Cell Biol., Natl. Inst. Infect. Dis., 7. Grad. Sch. Med., Tohoku Univ.)

[27-61-am-26S]Evaluation of the efficacy of a COVID-19 vaccine with enhanced antigen expression

○Ryoka Shimizu1, Rin Takasaki1 , Izumi Akiya1, Kaho Matsushita1, Akiko Hirose1, Mitsuhiro Iyori1,2 (1. Sch. Pharm., Musashino Univ., 2. Res. Inst. Pharm. Sci., Musashino Univ.)

[27-61-am-27]Analysis of inhibition mechanism of hepatitis B virus infection by butyrolactone I

○Chie Aoki Utsubo1, Hak Hotta1, Masanori Kameoka1 (1. Kobe Univ. Grad. Sch. Health Sci.)

[27-61-am-28]Development and characterization of anti-Oz virus glycoprotein monoclonal antibodies.

○Yoshimi Shimizu1,2, Yoko Inamori1, Yuta Homma1,3, Toshiyuki Yamaji1,3, Haruhiko Isawa4, Masayoshi Fukasawa1 (1. Department of Biochemistry and Cell Biology, NIID, JIHS., 2. School of Medicine, Showa Medical Univ., 3. Fac.Pharm.Sci., Juntendo Univ., 4. Department of Medical Entomology, NIID, JIHS.)

[27-61-am-29]Characterization of a simian endogenous retrovirus in the genome of a vaccine cell substrate, Vero cell

○Kyoko Saito1, Toshiyuki Yamaji2, Masayoshi Fukasawa1, Kentaro Hanada3 (1. Dept. Biochem. Cell Biol., Natl. Inst. Infect. Dis., Jap. Inst. Health Security, 2. Fac. Pharm., Juntendo Univ., 3. Dept. QC, Jap. Inst. Health Security)

[27-61-am-30]Analysis of the effects of broad-spectrum antiviral small molecule compounds on endocytosis

○Hirotaka Sato1, Ryosuke Muroyama1 (1. Sch. Med., Dokkyo Med. Univ.)
Back to Category List